Drugs / [11C]CPPC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06223971 | Aug 2024 → Apr 2025 | long COVID-19 | Johns Hopkins University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04749433 | Sep 2021 → Mar 2023 | amyotrophic lateral sclerosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05602142 | Aug 2026 → Jan 2027 expected | amyotrophic lateral sclerosis | Johns Hopkins University | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]CPPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05602142 ↗ |
| Modality | Diagnostic / imaging agent | “investigational radiotracer drug” NCT04749433 ↗ |
| Route | Intravenous | “will receive a single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously” NCT04749433 ↗ |
| Target | CSF1R | “highlights structures expressing colony stimulating factor receptor (CSF1R)” NCT04749433 ↗ |